We advised Arthex Biotech, a Spain-based startup, which closed a EUR 4.25m funding round, led by Advent France Biotechnology and the previous investor Invivo Ventures.
Arthex will use the new funds to ensure that its therapy will be first-in-human trial ready by 2022.
